Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31115079 | 0.76 | MAPT (0.49) | POLBLMNACYP1A2NPC1RAB9A | |
| SCHEMBL6748902 | 0.75 | POLB (0.33) | BTN3A1POLBLMNACA12CA9 | |
| SCHEMBL7859850 | 0.74 | KEAP1 (0.46) | POLBLMNACYP1A2CYP2C19MAPT | |
| SCHEMBL7140950 | 0.73 | EGFR (0.41) | LMNACYP1A2CYP2C19MAPT | |
| SCHEMBL187684 | 0.73 | ALOX5 (0.51) | POLBLMNACA12CA9NPC1 | |
| SCHEMBL6748905 | 0.72 | CYP2A6 (0.44) | LMNACYP1A2RAB9A | |
| SCHEMBL6750443 | 0.72 | AGXT (0.41) | LMNANPC1RAB9AMAPTTDP1 | |
| SCHEMBL6751272 | 0.71 | ALDH1A1 (0.43) | POLBNPC1RAB9AMAPTTDP1 | |
| SCHEMBL28242000 | 0.71 | MAPT (0.44) | LMNACYP2C19NPC1RAB9AKMT2A | |
| SCHEMBL4413665 | 0.70 | CYP1A2 (0.54) | POLBLMNACYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044045-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN, INC. | 2004-03-04 | — | — | US | disclosed |
| US-6602900-B2 | F-type prostaglandins as ocular hypotensives | ALLERGAN, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020198249-A1 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN SALES, INC. | 2002-12-26 | — | — | US | disclosed |
| US-6310087-B2 | TREATING GASTRIC OR DUODENAL ULCER, OSTEOPOROSIS, CONSTIPATION, RENAL DISORDERS, SEXUAL DYSFUNCTION, BALDNESS, DIABETES, CANCER AND DISORDER OF IMMUNE REGULATION | ALLERGAN SALES, INC. | 2001-10-30 | — | — | US | disclosed |
| US-20010016597-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN SALES, INC. | 2001-08-23 | — | — | US | disclosed |
| EP-0825980-B1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | ALLERGAN SALES INC (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6204287-B1 | TREATING VISION DEFECTS | ALLERGAN SALES, INC. | 2001-03-20 | — | — | US | disclosed |
| US-6037364-A | ADMINISTERING OCULAR HYPOTENSIVE AGENT; TREATING CARDIOVASCULAR DISORDERS; ANTICOAGULANTS | ALLERGAN SALES, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| US-5972991-A | ADMINISTERING TO THE MAMMAL SUFFERING FROM OCULAR HYPERTENSION A F-TYPE PROSTAGLANDIN DERIVATIVE | ALLERGAN (US) | 1999-10-26 | — | — | US | disclosed |
| US-5834498-A | OCULAR HYPOTENSIVE AGENTS | ALLERGAN (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0825980-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | Allergan (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996036599-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | ALLERGAN (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044045-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGFR, PTGER2 | BTN3A1 3197/4885POLB 1918/4885LMNA 1206/4885 |
| US-20010016597-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGER2, PTGFR | BTN3A1 3012/4885POLB 1745/4885LMNA 1131/4885 |
| US-20020198249-A1 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGFR, PTGER2 | BTN3A1 3298/4885POLB 1897/4885LMNA 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.